NGNE Neurogene PE ratio, current and historical analysis
The current PE ratio of NGNE cannot be calculated, as the latest EPS of -$4.28 is negative.
NGNE PE ratio history
How has NGNE's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
Neurogene PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $22.86 | -$4.28 |
| 2023 | N/A | N/A | $19.38 | -$117.28 |
| 2022 | N/A | N/A | $10.18 | -$139.88 |
| 2021 | N/A | N/A | $96.4 | -$22 |
| 2020 | N/A | N/A | $282 | -$12.8 |
| 2019 | N/A | N/A | $246.4 | -$51.4 |
| 2018 | N/A | N/A | $43.2 | -$26.8 |
| 2017 | N/A | N/A | $235.2 | -$42.8 |
| 2016 | N/A | N/A | $330.2 | -$39.2 |
| 2015 | N/A | N/A | $249.6 | -$34.6 |
| 2014 | N/A | N/A | $150 | -$55 |
| 2013 | N/A | N/A | N/A | -$990.4 |
| 2012 | N/A | N/A | N/A | -$804.6 |
Neurogene PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $22.86 | -$4.28 |
| Sep 2024 | N/A | N/A | $41.96 | -$32.9 |
| Jun 2024 | N/A | N/A | $36.39 | -$64.38 |
| Mar 2024 | N/A | N/A | $50.9 | -$89.97 |
| Dec 2023 | N/A | N/A | $19.38 | -$117.28 |
| Sep 2023 | N/A | N/A | $15.8 | -$211.55 |
| Jun 2023 | N/A | N/A | $16.6 | -$183.6 |
| Mar 2023 | N/A | N/A | $14 | -$162.52 |
| Dec 2022 | N/A | N/A | $10.18 | -$139.88 |
| Sep 2022 | N/A | N/A | $12.8 | -$21.32 |
| Jun 2022 | N/A | N/A | $20.6 | -$22.2 |
| Mar 2022 | N/A | N/A | $37.6 | -$22 |
| Dec 2021 | N/A | N/A | $96.4 | -$22 |
| Sep 2021 | N/A | N/A | $144.6 | -$21 |
| Jun 2021 | N/A | N/A | $184.6 | -$16.2 |
NGNE average PE ratio chart
What is the average PE ratio of NGNE for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
NGNE PE vs peers
What is NGNE's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $334.15M |
| OMER Omeros Corp | N/A | $422.12M |
| ONVO Organovo Holdings Inc | N/A | $2.52M |
| ORIC Oric Pharmaceuticals Inc | N/A | $361.53M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $91.51M |
| NGNE Neurogene Inc | N/A | $216.48M |
Frequently asked questions
What is Neurogene's PE ratio?
The current price to earnings ratio of NGNE cannot be determined, as its EPS of -$4.28 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.